Resonance Health Limited, a healthcare company, develops and delivers non-invasive medical imaging software and services in the Asia Pacific, North America, Europe, the Middle East, and Africa.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.12|
|52 Week High||AU$0.08|
|52 Week Low||AU$0.33|
|1 Month Change||20.00%|
|3 Month Change||-27.27%|
|1 Year Change||-25.00%|
|3 Year Change||313.79%|
|5 Year Change||328.57%|
|Change since IPO||-99.26%|
Recent News & Updates
|RHT||AU Medical Equipment||AU Market|
Return vs Industry: RHT underperformed the Australian Medical Equipment industry which returned -4.9% over the past year.
Return vs Market: RHT underperformed the Australian Market which returned 20.2% over the past year.
Stable Share Price: RHT is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: RHT's weekly volatility (10%) has been stable over the past year.
About the Company
Resonance Health Limited, a healthcare company, develops and delivers non-invasive medical imaging software and services in the Asia Pacific, North America, Europe, the Middle East, and Africa. Its principal product is FerriScan, a non-invasive liver diagnostic technology used for the measurement of liver iron concentration (LIC). The company also provides FerriSmart, an artificial intelligence (AI) driven system for the automated real-time measurement of LIC; HepaFat-AI, an AI driven system for the automated real-time multi-metric measurement of liver fat; Cardiac T2, a dual analysis service with FerriScan to provide information regarding body iron stores; HepaFat-Scan, a non-invasive MRI-based solution for the measurement of volume fraction of fat in liver tissue; and Bone Marrow R2-MRI for the assessment of iron levels in the bone marrow.
Resonance Health Fundamentals Summary
|RHT fundamental statistics|
Is RHT overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|RHT income statement (TTM)|
|Cost of Revenue||AU$0|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||0.0013|
|Net Profit Margin||15.50%|
How did RHT perform over the long term?See historical performance and comparison
Is Resonance Health undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: RHT (A$0.12) is trading above our estimate of fair value (A$0.03)
Significantly Below Fair Value: RHT is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: RHT is poor value based on its PE Ratio (94.5x) compared to the Australian Medical Equipment industry average (13.8x).
PE vs Market: RHT is poor value based on its PE Ratio (94.5x) compared to the Australian market (19.8x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate RHT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: RHT is overvalued based on its PB Ratio (4.7x) compared to the AU Medical Equipment industry average (4.5x).
How is Resonance Health forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Resonance Health has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Resonance Health performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: RHT has a large one-off gain of A$136.5K impacting its June 30 2021 financial results.
Growing Profit Margin: RHT became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: RHT has become profitable over the past 5 years, growing earnings by 30.2% per year.
Accelerating Growth: RHT has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: RHT has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (74.9%).
Return on Equity
High ROE: RHT's Return on Equity (5%) is considered low.
How is Resonance Health's financial position?
Financial Position Analysis
Short Term Liabilities: RHT's short term assets (A$9.7M) exceed its short term liabilities (A$611.7K).
Long Term Liabilities: RHT has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: RHT is debt free.
Reducing Debt: RHT has not had any debt for past 5 years.
Debt Coverage: RHT has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: RHT has no debt, therefore coverage of interest payments is not a concern.
What is Resonance Health current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate RHT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate RHT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if RHT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if RHT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of RHT's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mitchell Wells (46 yo)
Mr. Mitchell M. Wells, LLB, B. Comm., served as Company Secretary at Resonance Health Limited since April 2021 until May 31, 2021. He served as Non-Executive Director of Resonance Health Ltd. since Februar...
Experienced Management: RHT's management team is considered experienced (2.4 years average tenure).
Experienced Board: RHT's board of directors are considered experienced (7.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.8%.
Resonance Health Limited's employee growth, exchange listings and data sources
- Name: Resonance Health Limited
- Ticker: RHT
- Exchange: ASX
- Founded: 1987
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: AU$53.032m
- Shares outstanding: 461.15m
- Website: https://www.resonancehealth.com
- Resonance Health Limited
- 141 Burswood Road
- Ground Floor, Suite 2
- Western Australia
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/18 07:04|
|End of Day Share Price||2021/10/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.